載入中
LivaNova PLC is a global medical technology company dedicated to developing, manufacturing, and marketing a variety of therapeutic solutions. The company operates through three key segments. Its Cardiopulmonary division provides essential products for heart-lung procedures, such as oxygenators, heart-lung machines, and various perfusion systems. The Neuromodulation segment is known for its VNS Therapy System, an implantable device that delivers vagus nerve stimulation to treat drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. This segment is also advancing the VITARIA System, which employs VNS for heart failure, through clinical development. The Advanced Circulatory Support segment offers temporary life support solutions, including both cardiopulmonary and respiratory support technologies. LivaNova serves a wide range of medical professionals, including perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals and healthcare providers. The company's products are distributed globally through both its direct sales force and independent distributors. Additionally, LivaNova has a research collaboration with Verily aimed at discovering clinical biomarkers for depression. Founded in 1987, the company is headquartered in London, United Kingdom.
一般交易時段
US$75.0641
−US$0.8659 · -1.14%
盤中時間採用ET。市場資料可能有所延遲。
LivaNova PLC is a global medical technology company dedicated to developing, manufacturing, and marketing a variety of therapeutic solutions. The company operates through three key segments. Its Cardiopulmonary division provides essential products for heart-lung procedures, such as oxygenators, heart-lung machines, and various perfusion systems. The Neuromodulation segment is known for its VNS Therapy System, an implantable device that delivers vagus nerve stimulation to treat drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. This segment is also advancing the VITARIA System, which employs VNS for heart failure, through clinical development. The Advanced Circulatory Support segment offers temporary life support solutions, including both cardiopulmonary and respiratory support technologies. LivaNova serves a wide range of medical professionals, including perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals and healthcare providers. The company's products are distributed globally through both its direct sales force and independent distributors. Additionally, LivaNova has a research collaboration with Verily aimed at discovering clinical biomarkers for depression. Founded in 1987, the company is headquartered in London, United Kingdom.
日內區間
目前US$75.0641
52週區間
目前US$75.0641
盤中時間採用ET。市場資料可能有所延遲。
LivaNova PLC is a global medical technology company dedicated to developing, manufacturing, and marketing a variety of therapeutic solutions. The company operates through three key segments. Its Cardiopulmonary division provides essential products for heart-lung procedures, such as oxygenators, heart-lung machines, and various perfusion systems. The Neuromodulation segment is known for its VNS Therapy System, an implantable device that delivers vagus nerve stimulation to treat drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. This segment is also advancing the VITARIA System, which employs VNS for heart failure, through clinical development. The Advanced Circulatory Support segment offers temporary life support solutions, including both cardiopulmonary and respiratory support technologies. LivaNova serves a wide range of medical professionals, including perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals and healthcare providers. The company's products are distributed globally through both its direct sales force and independent distributors. Additionally, LivaNova has a research collaboration with Verily aimed at discovering clinical biomarkers for depression. Founded in 1987, the company is headquartered in London, United Kingdom.
日內區間
目前US$75.0641
52週區間
目前US$75.0641
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 13.88億 USD | 12.53億 USD | 11.54億 USD | 10.22億 USD | 10.35億 USD |
| 銷貨成本 | 4.48億 USD | 3.83億 USD | 3.82億 USD | 3.15億 USD | 3.29億 USD |
| 毛利 | 9.4億 USD | 8.71億 USD | 7.71億 USD | 7.07億 USD | 7.06億 USD |
| 研究與開發 | 1.86億 USD | 1.83億 USD | 1.94億 USD | 1.56億 USD | 1.83億 USD |
| 銷售、一般及管理費用 | 5.49億 USD | 5.26億 USD | 5.18億 USD | 4.69億 USD | 4.72億 USD |
| 營業費用 | 7.41億 USD | 7.42億 USD | 8.4億 USD | 7.84億 USD | 7.07億 USD |
| 利息收入 | 1898.2萬 USD | 3007.5萬 USD | 2201.2萬 USD | 469.7萬 USD | 43.5萬 USD |
| 利息支出 | 4928.6萬 USD | 6307萬 USD | 5885.3萬 USD | 4825萬 USD | 5015.1萬 USD |
| 折舊和攤銷 | 4200萬 USD | 5114.4萬 USD | 6085.6萬 USD | 5779.6萬 USD | 6798.8萬 USD |
| 營業利益 | 1.99億 USD | 1.29億 USD | −6849.8萬 USD | −7675.2萬 USD | −78.4萬 USD |
| 淨利 | −2.43億 USD | 6323.4萬 USD | 1754.6萬 USD | −8624.6萬 USD | −1.36億 USD |
公司資料更新於 2026年10月8日。
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
第三方分析師預期可能變動，並非 GoAI 建議。
報告持有此股票曝險的交易所交易基金。
Avantis U.S. Small Cap Value ETFAVUV1.2億0.39%305.4億 USD0.25%US$119.36+0.19%
iShares Russell 2000 ETFIWM1.12億0.14%785.63億 USD0.19%US$275.95-0.63%
Vanguard Extended Market ETFVXF5094.27萬0.05%954億 USD0.05%US$232.2-0.55%
Dimensional - US Targeted Value ETFDFAT3851.82萬0.13%300.02億 USD0.33%US$67.10+0.03%
Invesco S&P MidCap Momentum ETFXMMO3459.61萬0.49%72.53億 USD0.34%US$148.05-0.18%
Dimensional - US Small Cap ETFDFAS3171.55萬0.09%336.6億 USD0.31%US$77.715-0.26%
State Street SPDR S&P MIDCAP 400 ETF TrustMDY3168.11萬0.12%259.8億 USD0.23%US$663.42-0.08%
Invesco S&P MidCap Quality ETFXMHQ3145.04萬0.58%54.77億 USD0.30%US$112.7+0.04%Avantis U.S. Small Cap Value ETFAVUViShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFDimensional - US Targeted Value ETFDFATInvesco S&P MidCap Momentum ETFXMMODimensional - US Small Cap ETFDFASState Street SPDR S&P MIDCAP 400 ETF TrustMDYInvesco S&P MidCap Quality ETFXMHQAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
